• Bone Health
  • Immunology
  • Hematology
  • Respiratory
  • Dermatology
  • Diabetes
  • Gastroenterology
  • Neurology
  • Oncology
  • Ophthalmology
  • Rare Disease
  • Rheumatology

BLA Accepted for Fresenius Kabi Tocilizumab Biosimilar

Article

In a statement, Fresenius Kabi officials said the company is rapidly expanding its portfolio in autoimmune and oncology conditions.

FDA has accepted the biologics license application (BLA) for Fresenius Kabi’s biosimilar candidate for tocilizumab, the company announced earlier this week.

The candidate, MSB11456, would reference Actemra, an immunosuppressive drug used to treat autoimmune conditions that include moderate to severe rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, and systemic juvenile idiopathic arthritis.

According to a statement from the company, the BLA submission includes analytical similarity and comprehensive clinical data needed to demonstrate similar pharmacokinetic, efficacy, safety, tolerability, and immunogenicity to the reference product, with and without switch from tocilizumab to MSB11456. The application features presentations for both subcutaneous (prefilled syringe and autoinjector) and intravenous administrations. In its statement, the company said it anticipates FDA approval in 2023.

“The FDA’s acceptance of the BLA for our proposed tocilizumab biosimilar candidate is an important step forward in bringing a wider range of affordable and accessible autoimmune treatment options to patients and health care providers while reducing the cost burden to health care systems,” Michael Schönhofen, PhD, Fresenius Kabi chief operating officer and management board member, said in the statement. “We are rapidly expanding and investing in our biosimilars portfolio for autoimmune and cancer-related conditions, including R&D and manufacturing, to be a reliable biosimilars partner in the United States and worldwide.”

Fresenius Kabi recently acquired a majority stake at mAbxience, which strengthened its biosimilars portfolio and offered access to new manufacturing capabilities. The proposed tocilizumab biosimilar candidate would complement other products in a portfolio that includes the company’s adalimumab biosimilar, Idacio, which is commercialized in more than 34 countries and is under FDA review. 

Recent Videos
Sophia Humphreys, PharmD
Lakesha Farmer from Cencora
Prerakkumar Parikh, PharmD
Cencora's Corey Ford
Brian Biehn
Chelsee Jensen, PharmD, BCPS
GBW 2023 webinar
Fran Gregory, PharmD, MBA
Julie Reed
Julie Reed, executive director of the Biosimilars Forum
Related Content
© 2024 MJH Life Sciences

All rights reserved.